Search
News & Events
A cell change that drives leukaemiaIt is now known that the HOX11 gene is permanently activated in the leukaemia cells and it drives the disease.
News & Events
WA families to help find triggers for childhood leukaemiaWest Australian families are being asked to play a vital role in a major new national study to unravel the causes of childhood leukaemia.
Research
LeukaemiaLeukaemia, also spelled leukemia, is a cancer that develops in the bone marrow and results in abnormal white blood cells. It is the most common cancer in children, accounting for almost a third of all childhood & teen cancers.
Research
SNO-EANO-EURACAN consensus on management of pineal parenchymal tumorsPineal parenchymal tumors are rare neoplasms for which evidence-based treatment recommendations are lacking. These tumors vary in biology, clinical characteristics, and prognosis, requiring treatment that ranges from surgical resection alone to intensive multimodal antineoplastic therapy.
Research
Childhood leukaemia in Down's syndrome primed by blood-cell biasAn in-depth investigation of gene regulation and cell populations at sites of fetal blood-cell production provides clues as to why children with Down’s syndrome are predisposed to developing leukaemia.
Research
Editorial: Bench to bedside: translating pre-clinical research into clinical trials for childhood brain tumorsNick Raelene Gottardo Endersby MBChB FRACP PhD BSc (Hons) PhD Co-Head, Brain Tumour Research Brainchild Fellow; Co-Head, Brain Tumour Research
Research
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemiaOur study provides evidence that OT-82 is a promising new therapeutic strategy for a broad spectrum of high-risk pediatric acute lymphoblastic leukemia
Research
Bilateral murine tumor models for characterizing the response to immune checkpoint blockadeThis protocol describes bilateral murine tumor models that display a symmetrical yet dichotomous response to immune checkpoint blockade
Research
Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemiaThe aim of our study was to investigate whether CBL0137 has potential as a therapeutic and chemopotentiating compound in MLL-r leukemia
Research
Sensitizing the Tumor Microenvironment to Immune Checkpoint TherapyIn this review we explore the current literature about the predictive characteristics of the tumor microenvironment and discuss therapeutic approaches